These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 8261424)

  • 1. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S; Reuben JS; Streilein RD; Palker TJ
    J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy.
    Mor-Vaknin N; Turgeman H; Torgeman A; Wolfson M; Huleihel M; Aboud M
    Cell Biol Int; 1998; 22(2):95-103. PubMed ID: 9878096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
    Kuo CW; Mirsaliotis A; Brighty DW
    J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.
    Jacobson S; Shida H; McFarlin DE; Fauci AS; Koenig S
    Nature; 1990 Nov; 348(6298):245-8. PubMed ID: 2146511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and phylogenetic analyses of 16 novel simian T cell leukemia virus type 1 from Africa: close relationship of STLV-1 from Allenopithecus nigroviridis to HTLV-1 subtype B strains.
    Meertens L; Rigoulet J; Mauclère P; Van Beveren M; Chen GM; Diop O; Dubreuil G; Georges-Goubot MC; Berthier JL; Lewis J; Gessain A
    Virology; 2001 Sep; 287(2):275-85. PubMed ID: 11531406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.
    Tendler CL; Greenberg SJ; Burton JD; Danielpour D; Kim SJ; Blattner WA; Manns A; Waldmann TA
    J Cell Biochem; 1991 Aug; 46(4):302-11. PubMed ID: 1757474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of HTLV-1 gp46 glycoprotein from health carriers and HAM/TSP infected individuals.
    Mota-Miranda AC; Barreto FK; Amarante MF; Batista E; Monteiro-Cunha JP; Farre L; Galvão-Castro B; Alcantara LC
    Virol J; 2013 Mar; 10():75. PubMed ID: 23510700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay.
    Okuma K; Nakamura M; Nakano S; Niho Y; Matsuura Y
    Virology; 1999 Feb; 254(2):235-44. PubMed ID: 9986790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative analysis of the sequenced fragment of the Macaca arctoides STLV-1 env gene encoding the immunodominant region gp46 and the similar fragments in HTLV-1 (ATK) and STLV-1 from various primate species].
    Chikobava MG; Iakovleva LA; Indzhiia LV; Lapin BA
    Biull Eksp Biol Med; 1997 Jul; 124(7):92-6. PubMed ID: 9303743
    [No Abstract]   [Full Text] [Related]  

  • 19. Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.
    Furukawa K; Mori M; Ohta N; Ikeda H; Shida H; Furukawa K; Shiku H
    J Clin Invest; 1994 Nov; 94(5):1830-9. PubMed ID: 7962528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy.
    Kira J; Itoyama Y; Koyanagi Y; Tateishi J; Kishikawa M; Akizuki S; Kobayashi I; Toki N; Sueishi K; Sato H
    Ann Neurol; 1992 Jan; 31(1):39-45. PubMed ID: 1543349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.